286 related articles for article (PubMed ID: 37095427)
1. Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol.
Ros LAA; Goedee HS; Franssen H; Asselman FL; Bartels B; Cuppen I; van Eijk RPA; Sleutjes BTHM; van der Pol WL; Wadman RI
BMC Neurol; 2023 Apr; 23(1):164. PubMed ID: 37095427
[TBL] [Abstract][Full Text] [Related]
2. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
Markati T; Fisher G; Ramdas S; Servais L
Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
[TBL] [Abstract][Full Text] [Related]
3. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
[TBL] [Abstract][Full Text] [Related]
4. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
[TBL] [Abstract][Full Text] [Related]
5. Risdiplam: A Review in Spinal Muscular Atrophy.
Paik J
CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
[TBL] [Abstract][Full Text] [Related]
6. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
7. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.
Hjartarson HT; Nathorst-Böös K; Sejersen T
Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367
[TBL] [Abstract][Full Text] [Related]
8. One Year of Newborn Screening for SMA - Results of a German Pilot Project.
Vill K; Kölbel H; Schwartz O; Blaschek A; Olgemöller B; Harms E; Burggraf S; Röschinger W; Durner J; Gläser D; Nennstiel U; Wirth B; Schara U; Jensen B; Becker M; Hohenfellner K; Müller-Felber W
J Neuromuscul Dis; 2019; 6(4):503-515. PubMed ID: 31594245
[TBL] [Abstract][Full Text] [Related]
9. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
10. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments.
Salort-Campana E; Solé G; Magot A; Tard C; Noury JB; Behin A; De La Cruz E; Boyer F; Lefeuvre C; Masingue M; Debergé L; Finet A; Brison M; Spinazzi M; Pegat A; Sacconi S; Malfatti E; Choumert A; Bellance R; Bedat-Millet AL; Feasson L; Vuillerot C; Jacquin-Piques A; Michaud M; Pereon Y; Stojkovic T; Laforêt P; Attarian S; Cintas P
Orphanet J Rare Dis; 2024 Jan; 19(1):24. PubMed ID: 38268028
[TBL] [Abstract][Full Text] [Related]
13. The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy.
Arnold W; McGovern VL; Sanchez B; Li J; Corlett KM; Kolb SJ; Rutkove SB; Burghes AH
Neurobiol Dis; 2016 Mar; 87():116-23. PubMed ID: 26733414
[TBL] [Abstract][Full Text] [Related]
14. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen treatment of spinal muscular atrophy - a systematic review.
Albrechtsen SS; Born AP; Boesen MS
Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
[TBL] [Abstract][Full Text] [Related]
17. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
[TBL] [Abstract][Full Text] [Related]
18. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model.
Wang J; Bai J; OuYang S; Wang H; Jin Y; Peng X; Ge X; Jiao H; Zou J; He C; Xiao P; Song F; Qu Y
Hum Mol Genet; 2022 May; 31(10):1635-1650. PubMed ID: 34888619
[TBL] [Abstract][Full Text] [Related]
20. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]